On September 28, 2021 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), reported that the Company will participate in the following October investor conferences (Press release, Arbutus Biopharma, SEP 28, 2021, View Source [SID1234590395]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan’s 5th Annual Genetic Medicines Conference – Virtual (October 4-5, 2021)

Fireside Chat: Tuesday, October 5, 2021 at 4:30 pm ET
Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer
H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference (October 13, 2021)

Fireside Chat: Wednesday, October 13, 2021 at 1:00 pm ET
Presenters: William Collier, Dr. Michael Sofia, Dr. Gaston Picchio, and David Hastings
The live webcast links for the fireside chats can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.